reviewTop 10% cited
Pasireotide (SOM230): Development, mechanism of action and potential applications
Molecular and Cellular Endocrinology · 2007 · Vol. 286(1-2) · pp. 69–74
Herbert Schmid✉(Novartis (Switzerland))
Pituitary Gland Disorders and TreatmentsNeuroendocrine Tumor Research AdvancesGrowth Hormone and Insulin-like Growth FactorsPasireotideAcromegalySomatostatinSomatostatin receptorMedicineNeuroendocrine tumorsOctreotideCushing's diseaseInternal medicineEndocrinology
MeSH terms
AcromegalyAdrenocorticotropic HormoneAnimalsCarcinoid TumorHumansInsulin-Like Growth Factor ISomatostatinGrowth HormoneStructure-Activity RelationshipOctreotideReceptors, SomatostatinAntineoplastic Agents, HormonalDrug Resistance, NeoplasmPituitary ACTH Hypersecretion
Citations
286
FWCI
9.16
field-weighted impact
References
35
Percentile
99%
vs. same field & year
Citations per year
Cited by
Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours
Alimentary Pharmacology & Therapeutics · 2009 · 404 citations
References
SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile
European Journal of Endocrinology · 2002 · 683 citations
Related articles
Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours
Alimentary Pharmacology & Therapeutics · 2009 · 404 citations
Pasireotide (SOM230): Development, mechanism of action and potential applications
Molecular and Cellular Endocrinology · 2007 · 286 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.